Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Words of wisdom. Re: Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.

Bastian PJ.

Eur Urol. 2010 Nov;58(5):796. doi: 10.1016/j.eururo.2010.08.022. No abstract available.

PMID:
21414861
2.

Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance.

Loblaw A, Zhang L, Lam A, Nam R, Mamedov A, Vesprini D, Klotz L.

J Urol. 2010 Nov;184(5):1942-6. doi: 10.1016/j.juro.2010.06.101.

PMID:
20846681
3.
4.

Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.

Krakowsky Y, Loblaw A, Klotz L.

J Urol. 2010 Jul;184(1):131-5. doi: 10.1016/j.juro.2010.03.041.

PMID:
20478589
5.

Words of wisdom. Re: clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.

Ploussard G, Mongiat-Artus P.

Eur Urol. 2010 Jul;58(1):179-80. doi: 10.1016/j.eururo.2010.04.015. No abstract available. Erratum in: Eur Urol. 2010 Sep;58(3):474. Ploussar, Guillaume [corrected to Ploussard, Guillaume].

PMID:
20825750
6.

Words of wisdom: Re: Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.

Ploussard G, Mongiat-Artus P.

Eur Urol. 2011 Sep;60(3):597. doi: 10.1016/j.eururo.2011.06.012. No abstract available.

PMID:
21806912
7.

Words of wisdom. Re: Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.

Shteynshlyuger A, Kibel AS.

Eur Urol. 2009 Dec;56(6):1089-90. doi: 10.1016/j.eururo.2009.09.011. No abstract available.

PMID:
20965041
9.
10.

Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.

van den Bergh RC, Roemeling S, Roobol MJ, Wolters T, Schröder FH, Bangma CH.

Eur Urol. 2008 Sep;54(3):505-16. doi: 10.1016/j.eururo.2008.06.040. Review.

PMID:
18585845
11.

Words of wisdom. Re: Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.

Thalmann GN.

Eur Urol. 2009 Nov;56(5):884-5. doi: 10.1016/j.eururo.2009.08.009. No abstract available.

PMID:
20965034
12.

Words of wisdom. Re: prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.

Schröder FH, Roobol MJ.

Eur Urol. 2007 Sep;52(3):921. No abstract available.

PMID:
17855856
13.

Words of Wisdom. Re: prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.

Terrone C.

Eur Urol. 2011 Feb;59(2):304-5. doi: 10.1016/j.eururo.2010.11.012. No abstract available.

PMID:
21414880
18.

Modeling prostate specific antigen kinetics in patients on active surveillance.

Zhang L, Loblaw A, Klotz L.

J Urol. 2006 Oct;176(4 Pt 1):1392-7; discussion 1397-8.

PMID:
16952640
20.

Insignificant prostate cancer and active surveillance: from definition to clinical implications.

Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schröder F.

Eur Urol. 2009 Jun;55(6):1321-30. doi: 10.1016/j.eururo.2009.02.028. Review.

PMID:
19286302
Items per page

Supplemental Content

Support Center